Sublingual fast dissolving niosomal films for enhanced bioavailability and prolonged effect of metoprolol tartrate

被引:56
作者
Allam, Ayat [1 ]
Fetih, Gihan [1 ]
机构
[1] Assiut Univ, Fac Pharm, Dept Pharmaceut, Assiut 71526, Egypt
关键词
anti-hypertensive; beta(1)-antagonist; pharmacokinetics; DRUG-DELIVERY SYSTEMS; IN-VITRO; FORMULATION; RELEASE; PHARMACOKINETICS; DESIGN; DEXTROMETHORPHAN; CARRIERS;
D O I
10.2147/DDDT.S113775
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The aim of the present work was to prepare and evaluate sublingual fast dissolving films containing metoprolol tartrate-loaded niosomes. Niosomes were utilized to allow for prolonged release of the drug, whereas the films were used to increase the drug's bioavailability via the sublingual route. Niosomes were prepared using span 60 and cholesterol at different drug to surfactant ratios. The niosomes were characterized for size, zeta-potential, and entrapment efficiency. The selected niosomal formulation was incorporated into polymeric films using hydroxypropyl methyl cellulose E15 and methyl cellulose as film-forming polymers and Avicel as superdisintegrant. The physical characteristics (appearance, texture, pH, uniformity of weight and thickness, disintegration time, and palatability) of the prepared films were studied, in addition to evaluating the in vitro drug release, stability, and in vivo pharmacokinetics in rabbits. The release of the drug from the medicated film was fast (99.9% of the drug was released within 30 minutes), while the drug loaded into the niosomes, either incorporated into the film or not, showed only 22.85% drug release within the same time. The selected sublingual film showed significantly higher rate of drug absorption and higher drug plasma levels compared with that of commercial oral tablet. The plasma levels remained detectable for 24 hours following sublingual administration, compared with only 12 hours after administration of the oral tablet. In addition, the absolute bioavailability of the drug (ie, relative to intravenous administration) following sublingual administration was found to be significantly higher (91.06%+/- 13.28%), as compared with that after oral tablet administration (39.37%+/- 11.4%). These results indicate that the fast dissolving niosomal film could be a promising delivery system to enhance the bioavailability and prolong the therapeutic effect of metoprolol tartrate.
引用
收藏
页码:2421 / 2433
页数:13
相关论文
共 65 条
[1]  
Abbas H.K., 2013, KERBALA J PHARM SCI, V6, P153
[2]   Niosome-Encapsulated Gentamicin for Ophthalmic Controlled Delivery [J].
Abdelbary, Ghada ;
El-gendy, Nashwa .
AAPS PHARMSCITECH, 2008, 9 (03) :740-747
[3]   Design and Evaluation of Controlled-Release Niosomes and Discomes for Naltrexone Hydrochloride Ocular Delivery [J].
Abdelkader, Hamdy ;
Ismail, Sayed ;
Kamal, Amal ;
Alany, Raid G. .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2011, 100 (05) :1833-1846
[4]   Pharmacokinetics and anti-hypertensive effect of metoprolol tartrate rectal delivery system [J].
Abou el Ela, Amal El Sayeh F. ;
Allam, Ayat A. ;
Ibrahim, Ehsan H. .
DRUG DELIVERY, 2016, 23 (01) :69-78
[5]   In-vitro and in-vivo evaluation of a matrix-controlled bromocriptine mesilate-releasing vaginal ring [J].
Acartürk, F ;
Altug, N .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 2001, 53 (12) :1721-1726
[6]   Study of the extent of ocular absorption of acetazolamide from a developed niosomal formulation, by microdialysis sampling of aqueous humor [J].
Aggarwal, Deepika ;
Pal, Dhananjay ;
Mitra, Ashim K. ;
Kaur, Indu P. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2007, 338 (1-2) :21-26
[7]   Transdermal drug delivery systems of a beta blocker: Design, in vitro, and in vivo characterization [J].
Aqil, M ;
Sultana, Y ;
Ali, A ;
Dubey, K ;
Najmi, AK ;
Pillai, KK .
DRUG DELIVERY, 2004, 11 (01) :27-31
[8]  
Arya A., 2010, INT J CHEMTECH RES, V2, P576
[9]   Niosomes as transdermal drug delivery system for celecoxib: in vitro and in vivo studies [J].
Auda, Sayed H. ;
Fathalla, Dina ;
Fetih, Gihan ;
El-Badry, Mahmoud ;
Shakeel, Faiyaz .
POLYMER BULLETIN, 2016, 73 (05) :1229-1245
[10]  
Auda SH, 2014, LAT AM J PHARM, V33, P1027